title: Olfactory neuroblastomas: an experience of 24 years.
abstract: Objective. The aim of this study was to evaluate clinicopathological findings and the efficacy of the treatment modalities used in patients with olfactory neuroblastomas. Study Design. Retrospective record review. Setting. Istanbul University, Cerrahpasa Medical Faculty, medical oncology outpatient clinic. Subjects and Methods. There were 3 stage A tumors, 5 stage B and 11 stage C according to the Kadish staging system. There were 5 grade I/II and 12 grade III/IV according to the Hyams' histopathologic system. Involvement to orbita was detected in eight patients at the time of diagnosis. Results. The median follow-up period was 23.7 months. The 5-year survival rate for the whole group was 26%. The stage A/B groups exhibited a better survival rate than the C group with 2-year survival rates being 25 versus 71% respectively (P = .008). The grade I/II groups exhibited a better survival rate than the grade III/IV groups with 2-year survival rates being 50 versus 16% respectively (P = .001). The group who had orbital involvement exhibited a poor survival rate than the group of patients who had no involvement of the orbital. Conclusion. In our study, tumor stage, histopathologic grading, involvement of the orbita, brain and bone marow metastases were the statistically significant prognostic factors.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, 34098 Istanbul, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Tural
authors.forename: Ozcan
authors.initials: O
authors.lastname: Yildiz
authors.forename: Fatih
authors.initials: F
authors.lastname: Selcukbiricik
authors.forename: Mehmet Akif
authors.initials: MA
authors.lastname: Ozturk
authors.forename: Yildiz
authors.initials: Y
authors.lastname: Keles
authors.forename: Buge
authors.initials: B
authors.lastname: Oz
authors.forename: Omer
authors.initials: O
authors.lastname: Uzel
authors.forename: Gokhan
authors.initials: G
authors.lastname: Demir
authors.forename: Nil Molinas
authors.initials: NM
authors.lastname: Mandel
references.citation: Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):835-42
references.pmid: 8244813
references.citation: Cancer. 1979 Sep;44(3):1087-94
references.pmid: 383268
references.citation: Neurosurgery. 1998 May;42(5):1029-37
references.pmid: 9588547
references.citation: Neurosurg Focus. 2002 May 15;12(5):e4
references.pmid: 16119902
references.citation: Anticancer Res. 1997 Jul-Aug;17(4A):2683-706
references.pmid: 9252701
references.citation: Laryngoscope. 1992 Aug;102(8):843-9
references.pmid: 1495347
references.citation: APMIS. 2002 Sep;110(9):639-45
references.pmid: 12529017
references.citation: Cancer. 2002 Jul 15;95(2):243-8
references.pmid: 12124822
references.citation: Cancer. 1976 Mar;37(3):1571-6
references.pmid: 1260676
references.citation: Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8
references.pmid: 14515089
references.citation: Strahlenther Onkol. 2003 Apr;179(4):233-40
references.pmid: 12707712
references.citation: Head Neck. 1995 Mar-Apr;17(2):114-8
references.pmid: 7558807
references.citation: Lancet Oncol. 2001 Nov;2(11):683-90
references.pmid: 11902539
references.citation: Laryngoscope. 2003 Mar;113(3):502-7
references.pmid: 12616204